XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.20

-1.7%

1:12 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (10791)	7/14/1999 7:55:00 PM
From: Robert K.	Read Replies (1) of 17367

PB. I will attempt to answer, but you can be assured its not as good a followup as cacaito will provide. According to the paper "many studies defining the therapeutic role for bpi during sepsis have been limited to acute studies or studies with very high bacterial load. In our study we used a less overwhelming bacteremia (2 logs less)" They used a hyperdynamic study approach I believe to more closely mimic clinical sepsis. Your other question , by what mechanism to reduce tnf etc.... IMO its prevention of lps-lbp from cd14 stimulation by bpi. cacatio.please correct me or add comments as need be. Thanks. BTW-the paper claims that ultimately it IS the reduced bacteria. IMO But think about what DOES actually get rid of LPS. (lbp probably) Also IMO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next